Dr. Wallace explained, "While our nanobot technology has achieved excellent penetration into the field of medicine it's limited by the need for explicit programming. Our next generation product will be self modifying, able to diagnose disease and then act therapeutically."
"What are our prospects for a release to market?" asked Micromedical's CEO.
"Animal testing has yielded excellent results but we've seen complications in human subjects. The nanobots are clustering in the brain. We don't know what they're doing in there, but we're seeing increases in IQ. The real problem is that our test subjects are beginning to think for themselves."